Next Article in Journal
Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib
Next Article in Special Issue
Antrocin Sensitizes Prostate Cancer Cells to Radiotherapy through Inhibiting PI3K/AKT and MAPK Signaling Pathways
Previous Article in Journal
Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants
Previous Article in Special Issue
Developments in Stereotactic Body Radiotherapy
Open AccessReview

Radiotherapy as a New Player in Immuno-Oncology

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ 08901, USA
Author to whom correspondence should be addressed.
Cancers 2018, 10(12), 515;
Received: 7 November 2018 / Revised: 10 December 2018 / Accepted: 11 December 2018 / Published: 14 December 2018
(This article belongs to the Special Issue New Developments in Radiotherapy)
Recent development in radiation biology has revealed potent immunogenic properties of radiotherapy in cancer treatments. However, antitumor immune effects of radiotherapy are limited by the concomitant induction of radiation-dependent immunosuppressive effects. In the growing era of immunotherapy, combining radiotherapy with immunomodulating agents has demonstrated enhancement of radiation-induced antitumor immune activation that correlated with improved treatment outcomes. Yet, how to optimally deliver combination therapy regarding dose-fractionation and timing of radiotherapy is largely unknown. Future prospective testing to fine-tune this promising combination of radiotherapy and immunotherapy is warranted. View Full-Text
Keywords: radiotherapy; radiation; immunotherapy; combination therapy; cancer; dose-fractionation; timing radiotherapy; radiation; immunotherapy; combination therapy; cancer; dose-fractionation; timing
Show Figures

Figure 1

MDPI and ACS Style

Wang, S.-J.; Haffty, B. Radiotherapy as a New Player in Immuno-Oncology. Cancers 2018, 10, 515.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop